Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Grace Therapeutics, Inc GRCE

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.


NDAQ:GRCE - Post by User

Bullboard Posts
Post by RAWCOLTYon Jan 16, 2020 11:42am
208 Views
Post# 30560594

Trading activity as Expected

Trading activity as ExpectedThe Trading of the shares after the trials has been very predictable Given the situation. We had a jump to the lows in the $0.70's immediately and then you had all the shorts covering which bounced shares to $1.20 mark now we have the shares settling in with the day traders that will buy when momentum on the buy side decreases durring the dull times of the days like 10-12 am and sell into the small rallies in the afternoon when people are afraid not to have the shares for any good news.
This is going to be a tuff period until we can get through all the Fog. I bought more in the $0.70's myself but haven't sold any... like everyone out there I am too waiting for something close to  the $2.00 mark to unload some shares. This is going to create tremendous overhang on the stock until we get any good news.

Suffering is good for the Soul they say... Well my Sould should be nice and healthy after this debacle is over with.
Bullboard Posts